Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 8;10(6):381.
doi: 10.3390/diagnostics10060381.

Platelet-Rich Plasma Ameliorates Cyclophosphamide-Induced Acute Interstitial Cystitis/Painful Bladder Syndrome in a Rat Model

Yung-Hsiang Chen  1   2   3 , Kee-Ming Man  4   5   6 , Wen-Chi Chen  1   2 , Po-Len Liu  7 , Kao-Sung Tsai  8 , Ming-Yen Tsai  9 , Yu-Tzu Wu  10 , Huey-Yi Chen  1   2
Affiliations

Platelet-Rich Plasma Ameliorates Cyclophosphamide-Induced Acute Interstitial Cystitis/Painful Bladder Syndrome in a Rat Model

Yung-Hsiang Chen et al. Diagnostics (Basel). .

Abstract

Background: Interstitial cystitis/painful bladder syndrome (IC/PBS) could be treated to ameliorate urothelial injury. Here, we investigated the efficacy of intravesical instillation with platelet-rich plasma (PRP) and hyaluronic acid for acute IC/PBS.

Methods: The effects of PRP and hyaluronic acid on the proliferation of normal human fibroblast cells (HFCs) were assessed. Additionally, thirty virgin female rats were randomized into five groups: group 1, saline-injected control; group 2, cyclophosphamide (CYP) plus intravesical instillation with normal saline; group 3, CYP plus intravesical instillation with hyaluronic acid (1 mg/mL); group 4, CYP plus intravesical instillation with PRP; and group 5, CYP plus intravesical instillation with PRP plus hyaluronic acid. A cystometry and histological assessments were performed. The expression of cell junction-associated protein zonula occludens-2 (ZO-2) and inflammatory cytokine interleukin 6 (IL-6) was also measured.

Results: Low dose PRP increased proliferation in HFCs. The acute IC/PBS rats showed significantly lower voiding interval values. Voiding interval values were significantly higher in the CYP plus intravesical instillation with PRP group than in the CYP-induced acute IC/PBS group. Additionally, the expression of ZO-2 was increased and IL-6 was decreased in the CYP plus intravesical instillation with PRP group compared with the CYP-induced acute IC/PBS group.

Conclusion: These findings suggest that PRP modulate urothelial repair, which ameliorate the increase in urination frequency in rats treated with CYP. Overall, PRP may confer potential benefits by acting as urothelial repair modulators.

Keywords: cyclophosphamide; interstitial cystitis; painful bladder syndrome; platelet-rich plasma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
A represented experimental photo for the analysis of cystometry.
Figure 2
Figure 2
Effects in different concentrations of platelet-rich plasma (PRP) on cell proliferation of human fibroblast cells (HFCs) evaluated by MTT assays. Data are presented as the mean ± SD of three experiments performed in triplicate. * p < 0.05 contrasted to the control group.
Figure 3
Figure 3
Cystometry traces between saline-injected control, cyclophosphamide (CYP) plus intravesical instillation with normal saline, CYP plus intravesical instillation with hyaluronic acid (1 mg/mL), CYP plus intravesical instillation with PRP, and CYP plus intravesical instillation with hyaluronic acid (1 mg/mL) plus PRP groups. The peaks in the cystometry indicate the detrusor contraction (overactivity was shown in each group). Voiding interval values are revealed in the different groups. Each bar represents the mean ± SD of six individual rats. * p < 0.05 compared to the control group. # p < 0.05 contrasted to the CYP group.
Figure 4
Figure 4
Average thickness of mucosa between saline-injected control; CYP plus intravesical instillation with normal saline; CYP plus intravesical instillation with hyaluronic acid (1 mg/mL); CYP plus intravesical instillation with PRP; and CYP plus intravesical instillation with hyaluronic acid (1 mg/mL) plus PRP groups. Each bar denotes the mean ± SD of six individual rats. * p < 0.05 contrasted to the control group.
Figure 5
Figure 5
Average thickness of submucosa between saline-injected control, CYP plus intravesical instillation with normal saline, CYP plus intravesical instillation with hyaluronic acid (1 mg/mL), CYP plus intravesical instillation with PRP, and CYP plus intravesical instillation with hyaluronic acid (1 mg/mL) plus PRP groups. Each bar denotes the mean ± SD of six individual rats. * p < 0.05 contrasted to the control group. # p < 0.05 compared to the CYP group.
Figure 6
Figure 6
Alteration of ZO-2 expression in the bladder as indicated by Western blot analyses between saline-injected control, CYP plus intravesical instillation with normal saline, CYP plus intravesical instillation with hyaluronic acid (1 mg/mL), CYP plus intravesical instillation with PRP, and CYP plus intravesical instillation with hyaluronic acid (1 mg/mL) plus PRP groups. Each bar denotes the mean ± SD of six individual rats. * p < 0.05 compared to the control group. # p < 0.05 contrasted to the CYP group.
Figure 7
Figure 7
Alteration of IL-6 expression in bladder as indicated by Western blot analyses between saline-injected control, CYP plus intravesical instillation with normal saline, CYP plus intravesical instillation with hyaluronic acid (1 mg/mL), CYP plus intravesical instillation with PRP, and CYP plus intravesical instillation with hyaluronic acid (1 mg/mL) plus PRP groups. Each bar denotes the mean ± SD of six individual rats. * p < 0.05 contrasted to the control group. # p < 0.05 compared to the CYP group.
See this image and copyright information in PMC

References

    1. Batista R., Vinagre N., Meireles S., Vinagre J., Prazeres H., Leao R., Maximo V., Soares P. Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. Diagnostics. 2020;10 doi: 10.3390/diagnostics10010039. - DOI - PMC - PubMed
    1. Akiyama Y., Luo Y., Hanno P.M., Maeda D., Homma Y. Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives. Int. J. Urol. 2020 doi: 10.1111/iju.14229. - DOI - PMC - PubMed
    1. Rahnama’i M.S., Marcelissen T., Apostolidis A., Veit-Rubin N., Schurch B., Cardozo L., Dmochowski R. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol. Neurourol. Urodyn. 2018;37:S99–S107. doi: 10.1002/nau.23493. - DOI - PubMed
    1. Patnaik S.S., Lagana A.S., Vitale S.G., Buttice S., Noventa M., Gizzo S., Valenti G., Rapisarda A.M.C., La Rosa V.L., Magno C., et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch. Gynecol. Obstet. 2017;295:1341–1359. doi: 10.1007/s00404-017-4364-2. - DOI - PubMed
    1. Meng E., Hsu Y.C., Chuang Y.C. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC) Low Urin Tract Symptoms. 2018;10:3–11. doi: 10.1111/luts.12214. - DOI - PubMed